Poetting Sierk 4

What Happened
Sierk Poetting, Chief Operating Officer of BioNTech SE (BNTX), received two equity awards on 2026-05-12: 12,586 option units and 10,069 performance share units (PSUs). The Form 4 records these as derivative acquisitions at $0 (standard for grants). The option grant carries an exercise price of EUR 89.38 (subject to an adjustment rule described in the filing). No immediate sale occurred — these are compensatory awards, not open-market purchases or sales.

Key Details

• Transaction date: 2026-05-12; Form 4 filed 2026-05-13 (timely filing).
• Transaction code: A (award/grant); reported acquisition value shown as $0 for each grant (derivative grant).
• Option specifics (12,586 units): exercise price EUR 89.38 (footnote F1); may be settled in ordinary shares, ADSs and/or cash at the supervisory board’s election (F3). Vesting: annual equal installments over 4 years starting on the first anniversary; exercisable after four years subject to performance and other conditions (F2).
• PSU specifics (10,069 units): each PSU equals the economic equivalent of one ordinary share; vesting in equal annual installments over 4 years starting on the first anniversary and becoming exercisable after four years subject to performance targets tied to the Nasdaq Biotechnology Index and continued service (F4). Settlement may be in ordinary shares, ADSs, cash or other form.
• Shares owned after the transaction: not disclosed in the provided filing excerpt.

Context
These awards are typical long-term incentive grants for executives. Options require a future exercise (and payment of the exercise price) and PSUs vest only if service and performance conditions are met, so they do not represent immediately tradable shares or cash. Such grants are intended for retention and performance alignment and do not, by themselves, signal an insider buying or selling shares.